The trial demonstrated both efficacy and an improvement in quality of life, due in large part to the reduction in toxicity levels from lower dose chemotherapy. Highlights of the trial, which were compared to Eli Lilly’s (NYSE: LLY) Gemzar®, the current gold standard chemotherapy, include:
- Results demonstrated a 100% increase in patients’ median survival rate;
- The 1-year survival rate was twice that observed with the current gold standard;
- Chemotherapy dose needed was only one-third the normal amount;
- Improved quality of life was noted in more than half of the patients.
In the US alone, 37,000 people die every year from Pancreatic Cancer. It is widely regarded as the single most aggressive form of cancer. Nuvilex is aggressively pursuing the next phase of development of this treatment technology.
With 3 hours till the closing bell, NVLX shares are trading up 20% to .085 on heavy volume of 11.5 million shares. Through yesterday’s close, NVLX average daily volume over the last 3 months has been 1 million shares. At current levels, Nuvilex commands a $28 million market cap.
Nuvilex, Inc. (NVLX) Stock Quote and News:
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the 
0 comments
Add your comment
Commenting is allowed only for registered users.